JP2017536414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536414A5 JP2017536414A5 JP2017545861A JP2017545861A JP2017536414A5 JP 2017536414 A5 JP2017536414 A5 JP 2017536414A5 JP 2017545861 A JP2017545861 A JP 2017545861A JP 2017545861 A JP2017545861 A JP 2017545861A JP 2017536414 A5 JP2017536414 A5 JP 2017536414A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- acid sequence
- amino acid
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 14
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 14
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 239000005557 antagonist Substances 0.000 claims 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000030533 eye disease Diseases 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 239000007951 isotonicity adjuster Substances 0.000 claims 2
- 239000012669 liquid formulation Substances 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 229940068977 polysorbate 20 Drugs 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000001488 sodium phosphate Substances 0.000 claims 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical group [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 102000009075 Angiopoietin-2 Human genes 0.000 claims 1
- 108010048036 Angiopoietin-2 Proteins 0.000 claims 1
- 102000009840 Angiopoietins Human genes 0.000 claims 1
- 108010009906 Angiopoietins Proteins 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 229960002833 aflibercept Drugs 0.000 claims 1
- 108010081667 aflibercept Proteins 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 210000001210 retinal vessel Anatomy 0.000 claims 1
- 230000007928 solubilization Effects 0.000 claims 1
- 238000005063 solubilization Methods 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462084003P | 2014-11-25 | 2014-11-25 | |
| US62/084,003 | 2014-11-25 | ||
| US201562147232P | 2015-04-14 | 2015-04-14 | |
| US62/147,232 | 2015-04-14 | ||
| US14/943,490 | 2015-11-17 | ||
| US14/943,490 US20160144025A1 (en) | 2014-11-25 | 2015-11-17 | Methods and formulations for treating vascular eye diseases |
| PCT/US2015/061543 WO2016085750A1 (en) | 2014-11-25 | 2015-11-19 | Methods and formulations for treating vascular eye diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201473A Division JP2021046431A (ja) | 2014-11-25 | 2020-12-04 | 血管性眼疾患を処置するための方法および製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017536414A JP2017536414A (ja) | 2017-12-07 |
| JP2017536414A5 true JP2017536414A5 (enExample) | 2018-12-27 |
Family
ID=56009149
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017545861A Pending JP2017536414A (ja) | 2014-11-25 | 2015-11-19 | 血管性眼疾患を処置するための方法および製剤 |
| JP2020201473A Pending JP2021046431A (ja) | 2014-11-25 | 2020-12-04 | 血管性眼疾患を処置するための方法および製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201473A Pending JP2021046431A (ja) | 2014-11-25 | 2020-12-04 | 血管性眼疾患を処置するための方法および製剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20160144025A1 (enExample) |
| EP (1) | EP3224278A4 (enExample) |
| JP (2) | JP2017536414A (enExample) |
| KR (1) | KR20170087950A (enExample) |
| CN (1) | CN107001457A (enExample) |
| AU (1) | AU2015353838A1 (enExample) |
| BR (1) | BR112017009807A2 (enExample) |
| CA (1) | CA2968522A1 (enExample) |
| CL (1) | CL2017001188A1 (enExample) |
| CO (1) | CO2017004715A2 (enExample) |
| EA (1) | EA201791168A1 (enExample) |
| IL (1) | IL252159B (enExample) |
| MA (2) | MA41028A (enExample) |
| MX (1) | MX2017006129A (enExample) |
| PE (1) | PE20170900A1 (enExample) |
| PH (1) | PH12017500834A1 (enExample) |
| SG (1) | SG11201703609UA (enExample) |
| WO (1) | WO2016085750A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2995971A1 (en) | 2005-03-25 | 2006-10-05 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations |
| EP2371865B1 (en) | 2006-04-07 | 2017-07-12 | Aerpio Therapeutics, Inc. | Antibodies that bind human protein tyrosine phosphatase beta (HPTP-ß) and uses thereof |
| AU2007261536C1 (en) | 2006-06-16 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| EP3556367A1 (en) | 2009-07-06 | 2019-10-23 | Aerpio Therapeutics, Inc. | Benzosulfonamide derivatives, compositions thereof, and their use in the treatment of cancer or metastasis |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| CA2850830A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| HK1218071A1 (zh) | 2013-02-21 | 2017-02-03 | Rsem, Limited Partnership | Sema3a在预防和治疗眼渗透性过高症中的抑制 |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| US11104730B2 (en) | 2013-11-20 | 2021-08-31 | Regeneren Pharmaceuticals, Inc. | Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors |
| CN106456614A (zh) | 2014-03-14 | 2017-02-22 | 爱尔皮奥治疗有限公司 | HPTP‑β抑制剂 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| JP6726734B2 (ja) * | 2015-03-26 | 2020-07-22 | アイコー，エルエルシー | 画像解析のためのシステム |
| ES2981607T3 (es) | 2015-09-23 | 2024-10-09 | Eyepoint Pharmaceuticals Inc | Activadores de Tie-2 para uso en el tratamiento de la presión intraocular |
| EP3397276A4 (en) | 2015-12-30 | 2019-12-18 | Kodiak Sciences Inc. | ANTIBODIES AND CONJUGATES THEREOF |
| JP7107914B2 (ja) | 2016-07-20 | 2022-07-27 | アイポイント ファーマシューティカルズ， インコーポレイテッド | ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体 |
| US20200056186A1 (en) | 2016-09-22 | 2020-02-20 | Rsem, Limited Partnership | Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence |
| US20190300607A1 (en) * | 2016-10-12 | 2019-10-03 | Daiichi Sankyo Company, Limited | Composition containing anti-robo4 antibody and other agents |
| EA201992630A1 (ru) * | 2017-05-06 | 2020-04-29 | Ридженерон Фармасьютикалз, Инк. | Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf |
| IL271237B2 (en) * | 2017-08-18 | 2024-10-01 | Regeneron Pharma | Image capillary isoelectric focusing for the analysis of protein variants in a sample matrix |
| US10973879B2 (en) * | 2017-11-30 | 2021-04-13 | Regeneron Pharmaceuticals, Inc. | Use of a VEGF antagonist to treat angiogenic eye disorders |
| JP7692699B2 (ja) * | 2017-12-22 | 2025-06-16 | サムスン バイオエピス カンパニー リミテッド | Ｖｅｇｆアンタゴニストを含む液体組成物 |
| JP7517988B2 (ja) | 2018-01-26 | 2024-07-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗ｖｅｇｆ剤を使用した血管新生障害の治療のための方法および組成物 |
| CN111699004A (zh) * | 2018-02-06 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 眼科疾病的治疗 |
| US12071476B2 (en) | 2018-03-02 | 2024-08-27 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
| US11667702B2 (en) | 2018-03-08 | 2023-06-06 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| CN108671229B (zh) * | 2018-05-08 | 2022-03-25 | 华博生物医药技术（上海）有限公司 | 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂 |
| IL318714A (en) | 2018-05-10 | 2025-03-01 | Regeneron Pharma | Formulations that include high concentrations of VEGF receptor fusion protein |
| WO2020037309A1 (en) * | 2018-08-17 | 2020-02-20 | Trican Biotechnology Co., Ltd. | Anti-angiogenesis fusion protein and uses thereof |
| CN109598628B (zh) * | 2018-11-30 | 2022-09-20 | 平安医疗健康管理股份有限公司 | 医保欺诈行为的识别方法、装置、设备及可读存储介质 |
| BR112021011290A2 (pt) | 2018-12-18 | 2021-11-03 | Novartis Ag | Formulação de solução de proteína contendo alta concentração de um anticorpo anti-vegf |
| CR20210435A (es) | 2019-02-18 | 2021-09-20 | Lilly Co Eli | Formulación de anticuerpos terapéuticos |
| AU2020264969B2 (en) | 2019-04-29 | 2025-06-05 | EyePoint, Inc. | Tie-2 activators targeting the schlemm's canal |
| CN110423281B (zh) * | 2019-07-31 | 2021-04-30 | 成都金唯科生物科技有限公司 | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CA3168512A1 (en) | 2019-11-25 | 2021-06-03 | Napoleone Ferrara | Long-acting vegf inhibitors for intraocular neovascularization |
| CN113493519B (zh) * | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
| EP4143846A1 (en) * | 2020-04-29 | 2023-03-08 | Novartis AG | A computer-implemented system and method for assessing a level of activity of a disease or condition in a patient's eye |
| JP2023525034A (ja) | 2020-05-08 | 2023-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法 |
| EP4183802A4 (en) * | 2020-06-22 | 2024-11-06 | Innovent Biologics (Suzhou) Co., Ltd. | ANTI-ANG-2 ANTIBODY AND ITS USE |
| KR102690020B1 (ko) * | 2020-07-24 | 2024-08-01 | (주)팬젠 | 안과용 액상 조성물 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| WO2005072772A1 (en) * | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| AU2007261536C1 (en) * | 2006-06-16 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| CA2665956A1 (en) * | 2009-05-07 | 2010-11-07 | Samir Patel | Combination treatment for ocular diseases |
| UY32665A (es) * | 2009-05-28 | 2010-12-31 | Glaxo Group Ltd | Proteinas de union al antigeno |
| US8980268B2 (en) * | 2009-07-29 | 2015-03-17 | Regeneron Pharamceuticals, Inc. | Methods for treating cancer by administering an anti-Ang-2 antibody |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20120189635A1 (en) * | 2009-07-29 | 2012-07-26 | Regeneron Pharmaceuticals, Inc. | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) |
| AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| SG191334A1 (en) * | 2011-01-13 | 2013-08-30 | Regeneron Pharma | Use of a vegf antagonist to treat angiogenic eye disorders |
| WO2013112438A1 (en) * | 2012-01-23 | 2013-08-01 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ang2 antibodies |
| NZ702201A (en) * | 2012-07-13 | 2018-01-26 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| RS61648B1 (sr) * | 2012-12-05 | 2021-04-29 | Novartis Ag | Kompozicije i metode za antitela koja ciljaju epo |
| JO3405B1 (ar) * | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| US20160159893A1 (en) * | 2013-07-11 | 2016-06-09 | Gabriela Burian | Use of a VEGF Antagonist in Treating Retinopathy of Prematurity |
| CN106062004A (zh) * | 2013-12-17 | 2016-10-26 | 科马布有限公司 | 人靶标 |
| US9914769B2 (en) * | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
-
2015
- 2015-11-17 US US14/943,490 patent/US20160144025A1/en not_active Abandoned
- 2015-11-18 MA MA041028A patent/MA41028A/fr unknown
- 2015-11-19 PE PE2017000901A patent/PE20170900A1/es unknown
- 2015-11-19 MA MA40306A patent/MA40306A1/fr unknown
- 2015-11-19 MX MX2017006129A patent/MX2017006129A/es unknown
- 2015-11-19 SG SG11201703609UA patent/SG11201703609UA/en unknown
- 2015-11-19 BR BR112017009807A patent/BR112017009807A2/pt not_active IP Right Cessation
- 2015-11-19 EP EP15862329.8A patent/EP3224278A4/en not_active Withdrawn
- 2015-11-19 CA CA2968522A patent/CA2968522A1/en not_active Abandoned
- 2015-11-19 AU AU2015353838A patent/AU2015353838A1/en not_active Abandoned
- 2015-11-19 CN CN201580063632.5A patent/CN107001457A/zh active Pending
- 2015-11-19 EA EA201791168A patent/EA201791168A1/ru unknown
- 2015-11-19 KR KR1020177017473A patent/KR20170087950A/ko not_active Withdrawn
- 2015-11-19 JP JP2017545861A patent/JP2017536414A/ja active Pending
- 2015-11-19 WO PCT/US2015/061543 patent/WO2016085750A1/en not_active Ceased
-
2016
- 2016-12-06 US US15/370,896 patent/US20170080086A1/en not_active Abandoned
-
2017
- 2017-05-05 PH PH12017500834A patent/PH12017500834A1/en unknown
- 2017-05-08 IL IL252159A patent/IL252159B/en active IP Right Grant
- 2017-05-10 CL CL2017001188A patent/CL2017001188A1/es unknown
- 2017-05-10 CO CONC2017/0004715A patent/CO2017004715A2/es unknown
-
2018
- 2018-12-28 US US16/235,221 patent/US11071780B2/en active Active
-
2020
- 2020-12-04 JP JP2020201473A patent/JP2021046431A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536414A5 (enExample) | ||
| JP2021046431A (ja) | 血管性眼疾患を処置するための方法および製剤 | |
| US9926369B2 (en) | Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody | |
| CN102549015B (zh) | 针对人血管生成素-2的高亲和力人抗体 | |
| CA2870338C (en) | Lyophilised and aqueous anti-cd40 antibody formulations | |
| JP2020114218A5 (enExample) | ||
| WO2020094122A1 (zh) | 一种TGF-β受体融合蛋白药物组合物及其用途 | |
| CN111971062A (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
| JP2016504416A (ja) | 抗ｐｄｇｆｒ−ベータ抗体及びそれらの使用 | |
| JP2016504416A5 (enExample) | ||
| CN102027015A (zh) | 抗cxcr4抗体 | |
| JP2014532072A5 (enExample) | ||
| US20160152717A1 (en) | Methods for treating dry eye disease by administering an il-6r antagonist | |
| JP2020520912A (ja) | 抗ｇｉｔｒアゴニスト抗体での癌の処置 | |
| WO2016122996A1 (en) | Vegfa/ang2 compounds | |
| JP2021507677A5 (enExample) | ||
| JP2024528724A (ja) | 抗ｐｄ－１抗体医薬組成物及びその使用 | |
| JP6002354B1 (ja) | Ａｎｇ２抗体 | |
| US20240425574A1 (en) | Anti-pdgf-b antibodies and pharmaceutical composition thereof | |
| KR20130133274A (ko) | Tgf-알파 및 에피레굴린에 결합하는 항체 | |
| JP2020518641A5 (enExample) | ||
| TWI859339B (zh) | 抗nrp1a抗體及其用於治療眼或眼部疾病之用途 | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| EP4519317A1 (en) | Multispecific binding molecules and methods of use thereof | |
| RU2021125763A (ru) | Биспецифическое антитело, специфически связывающееся с vegf и ang2 |